Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Barrett E, Fitzgerald P, Dinan TG, Cryan JF, Ross RP, Quigley EM, et al
While GLP-1 receptor agonists were developed to treat type 2 diabetes, many have demonstrated significant weight loss or weight maintenance effects
Normally, you can expect your order to arrive in 2-5 business days
In line with evidence accrued in patients with T2D, incretin-based therapies produced a favorable effect on traditional cardiovascular risk factors, such as lipids and blood pressure, and even reduced the risk of major cardiovascular events and heart failure-related events in individuals with obesity, as recently demonstrated for the first time in the SELECT trial with semaglutide 2.4 mg once-weekly
G.Boza-SerranoA.PaulusA.DenisQ.et al (2022)
( a ) Day 48 % change in body weight, ( b ) body weight over time, and ( c ) average daily food intake measured every 3 days
US$ 20.08
US$ 22.47
US$ 22.56
US$ 28.68
US$ 24.71
US$ 29.33
